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Metastasis the spread of cancer cells to distant organs, is the main cause of death for cancer patients. Metastasis is often mediated
by lymphatic vessels that invade the primary tumor, and an early sign of metastasis is the presence of cancer cells in the regional
lymph node (the ﬁrst lymph node colonized by metastasizing cancer cells from a primary tumor). Understanding the interplay
between tumorigenesis and lymphangiogenesis (the formation of lymphatic vessels associated with tumor growth) will provide
us with new insights into mechanisms that modulate metastatic spread. In the long term, these insights will help to deﬁne new
molecular targets that could be used to block lymphatic vessel-mediated metastasis and increase patient survival. Here, we review
the molecular mechanisms of embryonic lymphangiogenesis and those that are recapitulated in tumor lymphangiogenesis, with a
view to identifying potential targets for therapies designed to suppress tumor lymphangiogenesis and hence metastasis.
1.Introduction
The spread of cancer to secondary sites (metastasis) is the
main cause of morbidity for patients with solid tumors. Un-
derstanding of the molecular and cellular mechanisms that
underpin tumor metastasis is therefore an important goal in
cancer biology. Over a century ago, Stephen Paget proposed
a “seed and soil” theory in which tumor cells have their pro-
pensitytoseedcertainparticularlyfavourableorgans[1].For
instance, prostate cancer often metastasizes to bones, colon
cancer to the liver, and melanoma to the brain. This theory
reﬂects the need of cancer cells to ﬁnd a suitable milieu with
appropriate molecular and cellular characteristics to be able
to survive. In 1928, James Ewing suggested an alternative
metastatic theory, proposing that cancer cell metastasis de-
pends solely on available anatomical and mechanical routes
[2]. Although tumorigenic cells certainly need to access the
lymphatic or blood vascular system to spread, in accordance
with Ewing’s theory, they also have diﬀerent propensity to
seed some organs in favour of the others. It is clear that both
anatomical/mechanical and “seed and soil” theories partly
explain the metastatic pattern.
Recent studies have revealed that the lymphatic vascula-
ture is one of the major routes for tumor metastasis, raising
thepossibilitythatblockingtumorlymphangiogenesismight
prevent the very initial stage of tumor spreading from the
primary site. This review focuses on tumor lymphangiogen-
esis, its eﬀect on cancer metastasis, and how targeting tumor
lymphangiogenesis may provide a potential therapeutic
strategy to treat cancer metastasis.
2. Lymphatic Vascular Systemand Its Function
The structural and functional features of the lymphatic
vascular system make it particularly suited to a role as a
major route of metastasis. The lymphatic system plays a
vital role in maintaining tissue ﬂuid homeostasis by draining
protein-rich ﬂuid from the interstitial space back to the
general blood circulation. The lymphatic system is divided
into the conducting vessel network and lymphoid tissue. The
lymphatic vessel network consists of lymphatic capillaries,
precollectingvessels,collectingvessels,andthethoracicduct.
The initial lymphatic capillaries have a thin wall, built from
a single layer of endothelial cells, and play a role in taking
up the interstitial tissue ﬂuid. Because cell-to-cell contact in
these vessels is loose and specialized for ﬂuid uptake, they
are also well suited to invasion by cancer cells. Furthermore,
thelymphaticcapillariesaredistributedthroughoutthebody
except for some avascular tissues such as the epidermis, car-
tilage, cornea, hair, nails, and some vascularized organs such
as the brain and the retina (reviewed by [3]). Their broad
distribution in the whole body therefore also provides ready2 Journal of Oncology
routes for cancer cell metastasis. The larger lymphatic vessels
have a smooth muscle cell layer and basement membrane
surrounding the inner lining of endothelial cells (reviewed
by [4]). In addition, they also contain intraluminal valves,
which allow unidirectional ﬂow to the thoracic duct in order
to reach the general blood circulation (reviewed by [3]).
Lymphoid tissue includes structurally well-organized
lymph nodes and loosely organized lymphoid follicles. The
lymph nodes are located at intervals along the lymphatic
vascular tree and ﬁlter the lymph. The lymph node therefore
represents a preferred site for lodgement of metastasizing
cancer cells during tumorigenesis [5].
Another important function of the lymphatic system is
immune traﬃcking and surveillance. Through the lymphatic
network, immune cells from the peripheral tissues navigate
to regional lymph nodes in order to stimulate the immune
response [6]. This navigation is also critical in modulating
inﬂammatory lymphangiogenesis. Interestingly, this mecha-
nism can also be utilised by cancer cells to escape from the
primary tumor site and metastasize to the regional lymph
nodes (discussed later in part 4.2.3).
3. Embryonic Lymphatic Vessel Development
Since the lymphatic developmental program can be re-
activated during tumor lymphangiogenesis, it is important
to understand early lymphatic vessel development in the
embryo and the key factors involved in this process. It has
been suggested that lymphatic vessels in mammals arise in
the embryo from the preexisting blood vasculature and more
particularly from the cardinal vein (CV) [7, 8]. Lymphatic
endothelial cell (LEC) precursors from the CV migrate
outwards and form the lymph sac (LS), from which lym-
phatic vessels start to develop throughout the body, con-
necting to form either deep or superﬁcial lymphatic vessels
(Figure 1(a)). Recent molecular studies based on lymphatic
phenotypes of mutant mice have revealed several factors
that regulate these steps in the embryo (Table 1). In this
section, we will discuss the factors involved in establishing
the lymphatic vasculature in the embryo, as a prelude to dis-
cussion of factors that are also involved in adult pathological
conditions, especially tumor lymphangiogenesis.
3.1. Lymphatic Endothelial Cell Speciﬁcation and Expansion of
the Lymphatic Network
3.1.1. Lymphatic Endothelial Cell Speciﬁcation. During early
lymphatic vascular development, lymphatic endothelial
hyaluronan receptor-1 (LYVE-1) and vascular endothelial
growth factor receptor-3 (VEGFR-3) are ﬁrst expressed at
sites where lymphangiogenesis will occur in the cardinal vein
around 8.5dpc [43]. Later, polarized expression of SOX18 is
found in the dorsal-lateral side of the cardinal vein at 9.0dpc
[10]. SOX18 directly activates the transcription of Prox1
gene, which encodes the homeodomain transcription factor
PROX1 (prospero-related homeobox-1) [10]. In addition,
anothertranscriptionfactor,COUP-TFII,hasbeenidentiﬁed
as being essential for modulation of PROX1 expression in
the cardinal vein [44]. These SOX18+/COUP-TFII+/PROX1+
lymphatic endothelial precursor cells then delaminate from
the CV to form lymph sacs, the primary plexus of the
lymphatic vasculature, around 11.5dpc in mouse embryo
[43, 45]( Figure 1(a)).
3.1.2.ExpansionoftheLymphaticVascularNetwork. Adorso-
lateral gradient of VEGF-C guides the developing lymphatic
endothelial cells during this early phase [46]. Disruption
of Vegfc in mice, Xenopus tadpoles, and zebraﬁsh leads to
a defect in migration of early lymphatic endothelial cells
from the cardinal veins to form a lymphatic plexus [18–20].
VEGFR-3 is a speciﬁc receptor tyrosine kinase that binds
to VEGF-C and VEGF-D and is highly expressed by blood
endothelial cells (BECs) before the diﬀerentiation of lym-
phatic vasculature. However, its expression becomes restrict-
ed to lymphatic endothelial cells after 11.5dpc [47]. VEGF-
C/VEGFR-3 signalling induces proliferation, migration, and
survival of endothelial cells [48], and transgenic overexpres-
sion of VEGF-C in the skin promotes lymphangiogenesis
[49]. Maintenance of VEGF-C/VEGFR-3 signalling therefore
is important in regulation of lymphatic vascular expansion.
A coreceptor for VEGF-C, neuropilin receptor-2 (Nrp-
2), is also expressed only within the veins and lymphatics
[29]. Both VEGF-C and VEGF-D bind to Nrp-2, and this
ligand stimulation leads to internalization of Nrp-2 together
with VEGFR-3 [50]. This ﬁnding suggests that both Nrp-2
and VEGFR-3 together increase the aﬃnity of LECs toward
VEGF-C gradients during lymphatic development.
After LEC speciﬁcation and establishment of the lym-
phatic plexus, separation of the lymphatic vasculature from
the blood vasculature is one of the most critical stages
required to ensure proper function of the two vessel net-
works. Several key factors and diﬀerent cell types that are
involved in this process have been recently reviewed else-
where, including tyrosine kinase SYK and its adaptor protein
SLP-76, expressed by circulating endothelial progenitor cells,
and podoplanin and C-type lectin receptor 2 (CLEC-2),
expressed in platelets (see [51]f o rr e v i e w )( Table 1).
3.2. Lymphatic Vessel Remodelling and Maturation. The next
stages involved in the remodelling and maturation of the
lymphatic network include the formation of lymphatic
capillary network from the primary lymphatic plexus, and
theassemblyofcollectinglymphaticvesselswithrecruitment
of smooth muscle cells (SMCs) and formation of lymphatic
valves [27, 52]. Angiopoietin-2 (Ang2), a growth factor
binding to its receptor tyrosine kinase Tie2, has been found
to be involved in lymphatic maturation. Ang2 mutant mice
display an abnormal lymphatic network due to defective
recruitment of smooth muscle cells to the lymphatic col-
lecting vasculature [23]. Further, overexpression of Ang1,
Ang2, and Ang3/Ang4 in adult tissues promotes lymphatic
sprouting in vivo [53–55].
The role of transmembrane growth factor ephrin-B2 in
postnatal remodeling of lymphatic vasculature has also been
explored using mice that express a mutated form of ephrin-
B2 lacking the carboxy-terminal site for binding PDZ-
domain-containing proteins. These mutant mice displayedJournal of Oncology 3
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Figure 1: Embryonic lymphangiogenesis versus tumor lymphangiogenesis. (a) During early lymphatic vessel development, lymphatic
endothelial precursor cells (SOX18+/COUP-TFII+/PROX-1+) from the CV migrate outwards and form lymph sacs (LS), from which
lymphatic vessels start to extend throughout the body. (b) In a tumor microenvironment, various lymphatic growth factors are secreted
from tumor cells, inﬂammatory cells (e.g., TAMs), and stroma cells. These factors stimulate the formation of tumor neolymphatics, either
in the peritumoral or intratumoral area, which facilitate the intravasation of cancer cells into lymphatic vessels. Interestingly, several
key early factors in embryonic lymphangiogenesis also play critical roles during tumor lymphangiogenesis. In particular, SOX18 is not
required for maintenance of adult lymphatics but appears to be reactivated and regulate the formation of tumor neolymphatics. CV,
cardinal vein; LS, lymph sac; dpc, days coitum; GF, growth factor; LN, lymph node; DLN, draining lymph node; TAMs, tumor-associated
macrophages.
major lymphatic defects, including disturbed postnatal re-
modeling of their primary lymphatic capillary plexus, hy-
perplasia, and lack of luminal valve formation, whereas
the blood vasculature phenotype remained normal [30, 56,
57].
Taken together, it is clear that many factors are known to
beinvolvedincontrollingtheﬁnelytunedstagesoflymphatic
vessel development in the embryo (summarized in Table 1).
Understanding the early embryonic steps of lymphatic ves-
sel formation will increase our knowledge of how a devel-
opmental program is reactivated in the adult under patho-
logical condition, and the consequences of its dysregulation.
In the following section, we will discuss the process of adult
neo-lymphangiogenesis during pathological conditions, par-
ticularly in tumor metastasis.
4. Lymphangiogenesis andTumor Metastasis
4.1. Tumor Microenvironment: Stroma versus Tumor Vascula-
ture in Metastasis. Metastasis is a complex multistep process
identiﬁed as the invasion-metastasis cascade, beginning with
local invasion then intravasation of cancer cells into blood
and lymphatic vessels, transit of cancer cells through these
vascular trees, extravasation to the lymph node or distant
organs, micrometastasis with small cancer nodules, and
ﬁnally an invasion step in which micrometastasis becomes
macrometastasis [58]. The ability of cancer cells to metasta-
sizedependsonmanytriggerssuchastheintrinsicproperties
of the tumor itself and the tumor microenvironment [59].
Thetumormicroenvironmentconsistsofcancercells,non-
cancer cells (e.g., endothelial cells (ECs), cancer-associated4 Journal of Oncology
Table 1: Lymphangiogenic factors in the early steps of embryonic development and in adult.
Key factors
Defects in lymphatic vascular system
Human syndrome Mutant animals
Transcription factors
SOX18
Dominant-negative mutations of SOX18 have been
linked with hypotrichosis-lymphedema-telangiectasia
syndrome (OMIM no. 607823) [9].
Sox18-null mice are devoid of lymphatic vessels and
die in utero at 14.5dpc from a generalized oedema
[10].
COUP-TFII
Conditional inactivation of COUP-TFII during
embryogenesis causes edema, haemorrhage, and
blood-ﬁlled lymphatics [11].
PROX-1
(i) Prox1−/− is embryonic lethality at approximately
14.5 dpc due to lack of lymphatic vasculature [12].
(ii) Conditional loss of Prox1 function in the adult
has been shown to induce LECs to revert to a blood
vascular phenotype [13].
TBX1 TBX1 mutation causes DiGeorge human syndrome,
which is associated with multiple congenital anomalies.
Mouse embryos with conditional deletion of Tbx1 in
endothelial cells display widespread
lymphangiogenesis defects and have perinatal death
[14].
NFATc-1
(i) NFATc1-deﬁcient mice showed irregular
patterning of the LEC sprouting from the jugular
lymph sac [15].
(ii) NFATc-1 and FOXC2 are downstream of
VEGFR-3, cooperate in regulating the diﬀerentiation
of lymphatic capillaries and valves formation [16].
FOXC2
Mutation in transcription factor FOXC2 caused
lymphedema-distichiasis (LD) in human (OMIM no.
153400).
Foxc2−/− mice have abnormal lymphatic vascular
patterning, increased pericyte investment of
lymphatic vessels, and loss of valves in the collecting
vessels [17].
Growth factors
VEGF-C
(i) The disruption of VEGF-C in mice, Xenopus
tadpoles, and zebraﬁsh leads to a defect in migration
of early lymphatic endothelial cells away from
cardinal veins to form lymphatic plexus [18–20].
(ii) Vegfc−/− mouse embryos completely lack
lymphatic vasculature [18].
(iii) Vegfc−/−;V e gf d −/− double knockout fails to
recapitulate the early embryonic lethality observed
in Vegfr3−/− mice [21].
VEGF-D
VEGF-D deﬁciency mice displayed no lymphatic
vessel dysfunction, suggesting that VEGF-D is
dispensable and might not play a major role in
lymphatic development [22].
Angiopoietin-2
Ang2-mutant mice display an abnormal lymphatic
network due to defective recruitment of smooth
muscle cells to the lymphatic collecting vasculature
[23].
Adrenomedullin
AM-, calcrl-, RAMP2-null mice died midgestation
with formation of interstitial lymphedema. Loss of
AM signalling caused abnormal jugular lymphatic
vessels due to reduced LEC proliferation [24].
Receptors/transmembrane
proteins
VEGFR-3
Heterozygous tyrosine kinase-inactivating missense
point mutations of VEGFR-3 gene have been identiﬁed
as a major cause of the Milroy disease (OMIM no.
153100).
Vegfr3 knockout mice display cardiovascular defects,
severe blood vessel defects, and embryonic death
[25].
Integrin α9β1
(i) Integrin-α9β1-deﬁcient mice die after birth due
to chylothorax, an accumulation of lymph in pleural
cavity [26].
(ii) Integrin-α9-deﬁcient mice further were
described as having abnormal lymphatic valves and
impaired ﬂuid transport [27].Journal of Oncology 5
Table 1: Continued.
Key factors
Defects in lymphatic vascular system
Human syndrome Mutant animals
LYVE-1
(i) Mice lacking this receptor have normal lymphatic
vessels.
(ii) LYVE-1 is expressed at the site where
lymphangiogenesis will occur in the cardinal vein
around 8.5 dpc [3].
Podoplanin
Podoplanin−/− mice died at birth and have
lymphatic defects, associated with decreased
lymphatic transport, lymphedema and dilation of
lymphatic vessels [28].
Neuropilin-2
Nrp2−/− mice show absence or severe reduction of
small lymphatic vessels and capillaries during
development, while arteries, veins, and collecting
lymphatics developed normally [29].
Ephrin-B2
Mice expressing a mutated form of Ephrin-B2 have
major lymphatic defects, including disturbed
postnatal lymphatic remodeling, hyperplasia, and
lack of luminal valve formation, whereas the blood
vasculature remained normal [30].
Clp24, Claudin-like
protein of 24kDa
(i) Clp24 knockdown in Danio rerio and Xenopus
laevis display defective lymphatic development.
(ii) Clp24-/- mice have enlarged lymphatic vessels
with abnormal patterning and smooth muscle cell
recruitment [31].
Liprin β1
Knock-down liprin β1i nXenopus laevis tadpoles
using morpholino leads to edema, defective
assembly of lymphatic vessels [32].
Synectin
K n o c k d o w no fs y n e c t i ni nz e b r a ﬁ s hc a u s e si m p a i r e d
formation of the thoracic duct and defective
lymphangiogenic sprouting [33].
ALK1, activin
receptor-like kinase 1
(i) ALK1 is a member of TGF-β type I family of
receptors.
(ii) Blockade of ALK1 signalling using ALK1Fc
results in failed remodelling of lymphatic vascular in
neonatal mice [34].
Others
SYK and SLP-76
Loss of SYK or SLP-76 function results in embryonic
hemorrhage, arteriovenous shunting,
blood-lymphatic connections, and blood-ﬁlled
lymphatics [35].
CCBE1
Mutation in CCBE1 associates with the Hennekam
syndrome, a generalised lymphatic dysplasia in humans
[36].
CCBE1 has been identiﬁed as essential factor for
embryonic lymphangiogenesis and venous sprouting
in zebraﬁsh model [37].
Aspp1,
apoptosis-stimulating
protein of p53
Aspp1−/− mice have embryonic subcutaneous
edema, delayed lymphatic vessel formation, defective
lymphatic drainage function and mispatterned
collecting lymphatic vessels [38].
Emilin-1
Emilin1−/− mice result in hyperplasia, enlargement,
irregular pattern of lymphatic vessels with a
reduction of anchoring ﬁlaments [39].
miR-31,
microRNA-targeting
PROX1
Gain of miR-31 function leads to impaired venous
sprouting and lymphatic vascular development in
Xenopus and zebraﬁsh; miR-31 is identiﬁed as
negative regulator of lymphatic development [40].
Rac1, Rho family
GTPase
Deletion of endothelial Rac1 in mice causes impaired
lymphatic-blood vessel separation, identiﬁed by
edema, haemorrhage, and embryonic lethality,
whereas blood vessels remain normal [41].
Spred-1/2
Spred-1/2 -deﬁcient embryos display subcutaneous
haemorrhage, edema, dilated and blood-ﬁlled
lymphatic vessels and die in utero [42].6 Journal of Oncology
ﬁbroblasts (CAFs), mesenchymal stem cells (MSCs), tumor-
associated macrophages (TAMs)), and noncellular compo-
nents (extracellular matrix—ECM) [60]. Interaction be-
tween cancer cells and their adjacent microenvironment
leads to a signiﬁcant impact on the tumor progression
and metastasis (see for review [60]). For instance, tumor
chemoattractantsincludingcolony-stimulatingfactors(CSF-
1) [61, 62], CC chemokines [63], and VEGF [64]s t i m u l a t e
the recruitment of the inﬁltrating cells (e.g., monocytes/
macrophages) in the lymphatic and blood vessels towards
the tumor. Further, several factors secreted by tumors,
includinginterleukin-10,-4(IL-10,-4),transforminggrowth
factor-β (TGF-β), and CSF-1, can switch these TAMs into
p o l a r i z e dt y p eI Io rM 2m a c r o p h a g e s[ 65]. Importantly,
M2 macrophages have reduced T-cell activity, poor antigen-
presenting capacity and concomitantly release several pro-
tumorigenic factors (TGF-β,I L - 1 0 ) ,p r o a n g i o g e n i cf a c -
tors (VEGF, IL-1β), prolymphangiogenic factors (VEGF-C,
VEGF-D), and extracellular matrix proteases (matrix metal-
loproteinases—MMPs) [65, 66]. During tumorigenesis, con-
nective tissue growth factor (CTGF) is also highly expressed
[67], which may lead to continued activation of the TGF-β
signalling pathway [68]. Further, TGF-β secreted by tumor
cells or host inﬂammatory cells might induce ﬁbroblasts in
thetumormicroenvironmenttobecomeactivatedﬁbroblasts
(myoﬁbroblasts), which express high levels of α-smooth
muscle actin [69, 70]. These activated ﬁbroblasts in turn
produce MMPs, which cleave E-cadherin and therefore
further induce epithelial to mesenchymal transition (EMT)
[71]. Cancer cells undergoing EMT have increased invasive
abilitybecauseof their loose cell-to-cellcontactand acquired
mesenchymal properties [72]. In addition, TGF-β secreted
by tumors also can induce activin receptor-like kinase 1
(ALK1 receptor) expressed by ECs, leading to endothelial cell
proliferation, migration, remodelling [73], and eventually
triggering tumor angiogenesis or lymphangiogenesis.
All of the events and complex interactions in the tumor
microenvironment alter the nature of tumor stroma cells,
which in turn signiﬁcantly aﬀects tumor progression and
metastasis.However,sincecellmigrationthroughconnective
tissue is relatively diﬃcult and slow, cancer cells are able to
spread more quickly and eﬃciently via blood or lymphatic
vessels [60].
Here, we will focus on one aspect of the tumor microen-
vironment by examining tumor lymphangiogenesis and its
impact on tumor metastasis. Lymphatic vessels, which have
high permeability and a lack of tight junction structure com-
pared to blood vessels, are particularly accessible for tumor
cell invasion. Clinical studies on breast, cervical, head and
neck,andovariancancerhaverevealedthat,inmostpatients,
an early sign of cancer spread is metastatic cells located in
the regional draining lymph node [74]( r e v i e w e db y[ 5]).
Clinicalstudieshavealsoshownthattheprocessofmetastasis
occurs in an orderly pattern, starting from the primary
site, spreading through the lymphatic channel, and then to
regional sentinel lymph nodes before disseminating systemi-
cally to distant organs (Figure 1(b)). Studies of micrometas-
tasis in the sentinel lymph node have shown that 80%
of metastasis follows this pattern, whereas 20% showed
systemic metastasis bypassing the lymphatic system [75].
The lymphatic vasculature is thus one of the major routes
for tumor metastasis and therefore is considered a potential
target for blocking the spread of cancer.
4.2. Tumor Lymphangiogenesis: Cellular and
Molecular Mechanisms
4.2.1. Growth Factors Involved in Tumor Lymphangiogenesis.
During the 1990s, the ﬁrst lymphangiogenic factor, VEGF-
C, was identiﬁed [76]. Overexpression of VEGF-C by tumor
cells can induce lymphangiogenesis and increase metastasis
to the regional lymph node in a mouse model of breast and
pancreatic cancer [77–80]. As mentioned above, TAM has
also been identiﬁed as a stroma cell critically responsible for
production of lymphatic growth factors, VEGF-C, and -D
[66, 81]( Figure 1(b)). In addition, VEGF-C overexpression
induced enlargement of tumor-associated lymphatic vessels
that can increase lymph ﬂow and facilitate intravasation of
cancer cells into the lymphatics [77] (Figure 2(b)). VEGF-
C has been further shown to induce intercellular gaps that
facilitate entry of tumor cells into the lumen of the vessels
[82]. More than 65 studies have shown that VEGF-C ex-
pression correlates with lymph node metastasis and poor
prognosis in a range of human tumors [14, 83–89]. In pa-
tients with melanoma, mRNA levels of VEGF-C also corre-
late with stage of tumor progression [90].
Another structurally related lymphatic growth factor is
VEGF-D, which also can bind to VEGFR-3 and activate lym-
phangiogenesis [91]. VEGF-C and -D share a central VEGF
homology domain (VHD), containing receptor-binding
sites, ﬂanked by N- and C-terminal propeptides, which can
be proteolytically cleaved to produce mature forms with
higher aﬃnity to receptors [92, 93] .T h e s em a t u r ef o r m so f
VEGF-C and -D also can bind to VEGFR-2 and therefore can
also promote angiogenesis [94–96]. Vegf-d-deﬁcient mice
display a lack of lymphatic vascular phenotype, suggesting
that VEGF-D might not play a major role in embryonic
lymphatic vessel development [22, 97]. However, VEGF-
D has been shown to play a role in stimulation of tumor
neo-lymphangiogenesis, as the expression of VEGF-D in
tumor cells induced tumor lymphangiogenesis and lymph
node metastasis in several tumor mouse models [98, 99]. In
addition, vegf-d-null mice displayed a reduction in peritu-
moral lymphangiogenesis and lymph node metastasis in an
orthotopicpancreatictumormodel[100].AnalysisofVEGF-
C and -D expression level in excised patient tumor tissues
revealedthatlevelsofthesegrowthfactorsareassociatedwith
p o o ro u t c o m ea n dl y m p hn o d em e t a s t a s i s[ 101–103].
Another VEGF family member, VEGF-A, initially iden-
tiﬁed as a key positive regulator of angiogenesis, primar-
ily binds to VEGFR-1 and VEGFR-2 [104]. VEGF-A has
no known function during embryonic lymphangiogenesis.
However, VEGF-A has been shown to induce tumor lym-
phangiogenesis and tumor metastasis to regional and distant
lymph nodes [105], and VEGF-A overexpressing tumors
havehighnumbersofmacrophages[106].Further,Cursiefen
et al. (2004) have shown an indirect lymphangiogenic
role for VEGF-A via recruitment of bone marrow-derivedJournal of Oncology 7
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Figure 2: Biology of tumor lymphangiogenesis and metastasis. (A), (B) Stimulation of tumor neo-lymphangiogenesis and enlargement
of tumor lymphatics can facilitate intravasation of cancer cells into the lymphatics. (C) The interaction between tumor cells and LECs
via tumor cell receptors (e.g., Integrin α4β1) and endothelial cell adhesion molecules (e.g., VCAM-1) or via chemokine receptor ligand
interaction (e.g., CCR7/CCL21) can facilitate the invasion of cancer cells into lymphatic vessels (intralymphatic cancer cells). (E) Notably,
lymphangiogenesis also occurs at the tumor draining lymph node (DLN) before metastasis of cancer cells to this site, probably to generate a
favourable environment for in-coming metastatic cancer cells at this site. (F) Intralymphatic cancer cells then metastasize to the tumor DLN.
(D), (G) Additionally, tumor angiogenesis also contributes to distant organ metastasis. The tumor microenvironment has a critical impact
on tumor progression and metastasis. LECs, lymphatic endothelial cells; DLN, draining lymph node.
macrophages (BDMs) by using a mouse model of inﬂam-
matory-induced corneal neovascularization. These BDMs in
turn secrete angiogenic and lymphangiogenic factors that
can stimulate both blood and lymphatic out-growth [107].
Several other factors have been recently identiﬁed as
inducersoflymphangiogenesis, including hepatocytegrowth
factor, Angiopoietins 1 and 2 (Ang-1, -2), ﬁbroblast growth
factor-2 (FGF-2), platelet-derived growth factor-BB (PDGF-
BB), growth hormone (GH), adrenomedullin (AM), insulin-
like growth factors 1 and 2, and endothelin-1 (ET-1) (the
involvement of these factors in tumor lymphangiogenesis
is summarized in Table 2). Some of these factors have al-
ready been identiﬁed from embryonic lymphatic vessel de-
velopment studies, whereas others were discovered in tumor
lymphangiogenesis studies. Further studies aimed at inden-
tifying lymphangiogenic growth factors will help to provide
more potential molecule targets in inhibiting tumor neo-
lymphangiogenesis and metastasis.
4.2.2. Peritumoral and Intratumoral Lymphatics. The relative
distance of the tumor to the lymphatic bed can also aﬀect
the ability of cancer cells to metastasize. It is well established
that peritumoral lymphatics are predominantly responsible
for the uptake of cancer cells during metastasis [128]. In
fact, lymph node metastasis associated with melanoma can
be predicted more accurately by quantitation of peritumoral
lymphatic vessels than by quantitation of intratumoral ves-
sels [129]. Also in a clinical study on a cohort of 123 patients
with gastric cancer, peritumoral lymphatics were shown
to exhibit higher density when compared to intratumoral
lymphatics, and importantly these peritumoral lymphatics
also play a role in gastric cancer progression [130].
Incontrast,theroleofintratumorallymphaticvesselshas
remained unclear and controversial. Intratumoral lymphat-
ics have been thought to be nonfunctional and are typically
collapsed due to the high pressure found in intratumoural
environment [128]. Nevertheless, in a mouse model of
tumor overexpression of VEGF-C/VEGF-D, proliferation of
intratumoral lymphatics was shown to correlate with lymph
node metastasis [79, 98, 99, 131]. However, it still remains to
be clariﬁed whether function of intratumoral lymphatics is
critical for tumor invasion and distant organ metastasis.
4.2.3. Interaction between Tumor Cells and Lymphatic Vas-
culature. Interactions between tumor cell surface receptors
and endothelial cell adhesion molecules are thought to
contribute to tumor cell arrest and extravasation during
blood vessel-mediated metastasis. It has been shown that8 Journal of Oncology
Table 2: Tumor lymphangiogenic growth factors and their receptors.
Lymphangiogenic
factors Receptors Mechanism of action/association with cancer References
VEGF-C VEGFR-2,
VEGFR-3
(i) Overexpression of VEGF-C by tumor induces tumor
lymphangiogenesis, dilated lymphatics and increases metastasis to lymph
node.
(ii) Proteolytic VEGF-C also binds to VEGFR-2 and therefore can also
induce tumor angiogenesis
[77–80, 94]
VEGF-D VEGFR-2,
VEGFR-3
(i) VEGF-D plays a role in stimulation of tumor lymphangiogenesis and
lymph node metastasis.
(ii) Proteolytic VEGF-D also binds to VEGFR-2 and can induce tumor
angiogenesis.
[98–
100, 108]
VEGF-A VEGFR-2 (i) VEGF-A induces tumor lymphangiogenesis and tumor metastasis to
regional lymph node. [105]
FGF-2 FGFR-3
[109]
(i) Induces both angiogenesis and lymphangiogenesis through the control
of VEGF-C and VEGF-D expression.
(ii) Increased expression of FGF-2 is associated with lymphatic metastasis.
[110, 111]
Hepatocyte
growth factor
(HGF)
c-met
(i) Overexpression of HGF in mice/intradermal delivered HGF induces
lymphatic vessel hyperplasia.
(ii) HGF stimulate the outgrowth of peritumoral lymphatics, via activation
of VEGFR-3.
(iii) HGF contribute to lymphatic metastasis when overexpressed in tumor.
[112, 113]
Insulin-like
growth factor-1, 2
Insulin-like
growth
factor
receptor
(i) IGF-1, -2 induce lymphangiogenesis in a mouse cornea assay.
(ii) IGF-IR is involved in angiogenesis and lymphangiogenesis through
modulation of VEGF ligand expression in gastric cancer cell line MKN45.
[106, 114]
Ephrin-B2
Eph.
receptor
tyrosine
kinase
(i) PDZ interaction site in Ephrin-B2 is required for the remodelling of
lymphatic vasculature.
(ii) Tumor angiogenesis was inhibited in Ephrin-B-mutant mice in an
orthotopic glioma tumor model.
[30, 115]
Angiopoietin-1,
-2 (Ang-1, -2) Tie-2
(i) Overexpression of Ang-1 in adult mouse tissues leads to lymphatic
sprouting and hyperplasia.
(ii) Ang-1 is moderately expressed by tumor cells; Ang-2 is expressed by
activated endothelial cells and upregulated during tumorigenesis.
(iii) Ang-2 levels are associated with disease progression in melanoma
patients.
[55, 116,
117]
PDGF-BB PDGFR-α
and -β
Expression of PDGF-BB in murine ﬁbrosarcoma cells induced
intratumoral lymphangiogenesis and promote lymphatic metastasis [118]
Growth hormone
(GH)
Growth
hormone
receptor
(i) GH promotes lymphangiogenesis in the granulation tissue of
full-thickness skin wounds.
(ii) Ectopic GH expression has been found in breast cancer and pancreatic
cancer tissue.
[119–121]
Adrenomedulin
(AM)
Calcrl
associated
with
RAMP2 (∗)
AM is a multifunctional regulatory peptide that is overexpressed in cancer
cells and help them to develop to malignant growth. [122]
Endothelin-1
(ET-1)
Endotheline
Br e c e p t o r
(ETBR)
(i) ET-1/ETBR expression is correlated with lymphatic invasion in human
breast cancers.
(ii) ET-1/ETBR enhances VEGF-A/C and VEGFR-3 expression and induces
formation of lymphatic vessels.
(iii) ET-1 is one of signiﬁcantly upregulated genes in LEC isolated from
metastatic LN.
[123–125]
Neutrin-4
(i) Netrin-4 is expressed in human breast tumor lymphatic and blood
vessels.
(ii) In mouse model of netrin-4 overexpressing breast cancer, lymph node
metastasis and lung metastasis were signiﬁcantly increased.
(iii) Netrin-4 stimulates lymphatic permeability via activation of small
GTPase and Src family kinase/FAK and downregulating tight junction
protein.
[126]
Fibronectin Integrin
α4β1
High expression of integrin α4β1 is detected on tumor lymphatic
endothelium. [127]
∗Calcrl: calcitonin receptor-like receptor; RAMP2: receptor activity-modifying protein.Journal of Oncology 9
the interaction of melanoma cell integrin α4β1( v e r yl a t e
antigen-4, VLA-4) with VCAM-1 is critical for tumor cell
arrest [132, 133]. Therefore, the expression of VCAM-1 on
tumor lymphatics could lead to increased interaction with
cancer cells and further facilitate metastasis. In addition,
organ-speciﬁc increases in VCAM-1 expression correspond
with reported clinical patterns of melanoma metastasis [134,
135].
During inﬂammatory response, lymphatic vessels play a
critical role in the migration of dendritic cells to the drain-
ing lymph node to initiate the adaptive immune response
[6]. The inﬂammatory cells interact with the lymphatic en-
dothelium to ﬁnd their way to the next lymphatic vessels
and transmigrate into the vascular lumen [6]. Recent studies
have revealed that this interaction occurs through the spe-
cific expression of ligands and their receptors. Lymphatic
endothelium actively secretes the chemokine (C-C motif)
ligand 21 (CCL21), which binds to the C-C chemokine
receptor type 7 (CCR7) expressed on dendritic cells, thus
creating a chemoattracting gradient for dendritic cells that
migrate toward the lymphatic vasculature [136, 137]. In-
terestingly, tumor cells also can use this physiological
chemokine receptor/ligand interaction to metastasize to the
regional lymph node [138, 139]. In fact, CCR7 is expressed
in some malignant melanoma cell lines [140], and it has
been shown in melanoma mouse model that lymphatics can
attract cancer cells through secretion of endogenous che-
mokine [141, 142]. Human breast cancer cells express the
chemokine receptors CXCR4 and CCR7 [140]. Further, their
respective ligands CXCL12 and CCL21 are highly expressed
in the target organs of breast cancer metastasis that can
partly explain the metastatic pattern in breast cancer patients
[140]. In addition, ﬁbroblasts, which constitute the majority
of stromal cells in the tumor microenvironment of breast
carcinoma, play an important role in establishment of the
CXCL12-CXCR4 axis. In fact, CAFs elevate CXCL12 secre-
tion,whichinturncanstimulateproliferationandmigration
of CXCR4-expressing cancer cells in the tumor microenvi-
ronment [143, 144].
Understanding the interaction between tumor cells and
LECs can help to identify an alternative way to block the
intravasation of cancer cells into lymphatics. Inhibiting key
factorsinvolvedinthisprocesswouldprovidenovelpotential
therapeutic solution.
4.2.4. Intralymphatic Cancer Cells. Lymphatic invasion at
either the primary tumor site or distant metastatic organs is
characterisedbytheexistenceofcancercellsinsidethelumen
of the lymphatic vasculature (intralymphatic cancer cells or
tumor emboli). The frequency of lymphatic invasion has
been investigated in melanoma and gastric and breast cancer
[145–147]. Importantly, it has been shown that lymphatic
invasion occurs more frequently than blood vessel invasion
(16%versus3%inmelanoma)[145–147].75%ofmelanoma
patients that present intratumoral or peritumoral lymphatic
invasion also exhibit sentinel lymph node metastasis [145].
Lymphatic invasion is therefore one of the most important
adverse prognostic indicators for cancer recurrence rate and
sentinel lymph node metastasis [145, 146, 148, 149].
Intralymphatic cancer cells have been also detected in
distant organs. In a study using a mouse model of lym-
phangitic carcinomatosis, an extremely aggressive form of
lung metastasis, cells expressing VEGF-C were speciﬁcally
identiﬁed inside the peribronchial lymphatic vessels [150].
This observation suggests that conditioning of the intra-
lymphatic vessel milieu with particular factors may have
growth-promoting activity, which in turn facilitates tumor
survival and promotes metastasis [150]. Since cancer cells re-
mainessentiallyintra-lymphaticanddonotinvadethealveo-
lar region, lungs still remain functional until a very advanced
stage of the disease. This model of lung cancer metastasis
recapitulates the human cancer situation in which patients
with pulmonary lymphangitic carcinomatosis typically do
not experience symptoms until a very late stage of disease
when cancer cells start to extravasate from the lymphatics to
invade the alveolar region of the lung [150].
4.2.5. Neo-Lymphangiogenesis in the Tumor Draining Lymph
Node. It has been shown that the primary tumor has the
ability to induce neo-lymphangiogenesis in the lymph node
itself, so as to establish a “platform” from which cancer cells
can disseminate [105, 129, 151, 152] (Figure 2(e)). VEGF-A-
overexpressingprimarytumorsinducelymphangiogenesisat
the sentinel lymph node even before cancer cells metastasize
to this site [105]. Further, in mouse models of skin carcino-
genesis in which VEGF-C was overexpressed in skin, lym-
phangiogenesis occurred at both the primary tumor site and
the tumor draining lymph nodes [151]. VEGF-A and VEGF-
C secreted from the primary tumor site can be drained to the
regional lymph node where lymphangiogenesis is stimulated
prior to the invasion of metastatic cancer cells. Once cancer
cells metastasize to the regional lymph node, lymphangio-
genesis is further enhanced [105, 151]. This observation
indicates that lymphangiogenesis in the premetastatic lymph
nodecreatesafavourableenvironment,apremetastaticniche
that might support the survival of in-coming metastatic
cancer cells [83]. Tumor-induced neo-lymphangiogenesis in
the regional lymph node triggers an increase of lymph ﬂow.
This upregulation in ﬂow is a permissive factor that can
actively enhance metastatic rate via the lymphatics [153].
Importantly, lymph node lymphangiogenesis is also detected
in cancer patients suﬀering from melanoma and breast can-
cer [154, 155], two cancer types known for their high rate of
metastasis.
Additionally, neo-lymphangiogenesis in a distant organ
has also been investigated in a mouse model of breast cancer
cells that overexpress VEGF-C [150]. The induction of lym-
phangiogenesis by VEGF-C at a secondary tumor site in the
lung was shown to facilitate the expansion of already dissem-
inated cancer cells throughout the lung tissue [150].
4.3. Cellular Origin of Tumor Lymphatic Endothelial Cells
4.3.1. Neolymphatic Vessels Arise Mainly from the Preexisting
Vasculature. Identifying the cellular origin of tumor LECs
can help to identify targets for anti-lymphangiogenic drugs
in tumors. Growth of lymphatic vessels from preexisting ves-
sels (neo-lymphangiogenesis) is regionally induced during10 Journal of Oncology
(A) Preexisting lymphatic vessels
(C) Preexisting blood vessels
Transdifferentiation
Transdifferentiation
SOX18/COUP-TFll/PROX1
LECs proliferation and migration
VEGF-C/D/A and other lymphatic GFs
(B) Bone marrow-derived endothelial
progenitor cells (e.g, TAMs) LYVE-1/VEGFR-3
Neolymphatic
outgrowth
Tumor
neolymphatics
Figure 3: Potential cellular origins of tumor lymphatic endothelial cells. (A) Neolymphatics mainly arise from preexisting vasculature by
proliferation and migration of LECs. (B) Bone marrow-derived endothelial progenitor cells (e.g., tumor-associated macrophages—TAMs)
can also transdiﬀerentiate into LECs, which further incorporate into the pre-existing lymphatic vasculature. (C) BECs can transdiﬀerentiate
into LECs under stimulation of reexpressed lymphatic transcription factors and lymphatic growth factor receptors. This mechanism has not
been shown in in vivo (dashed line arrow).
tumorigenesis (Figure 3(a)). There is a strong body of ev-
idence in the literature suggesting that neolymphatics mainly
arise from preexisting lymphatic vessels, whereas bone mar-
row-derived endothelial progenitor cells did not signiﬁcantly
contribute to the formation of tumor lymphatic vessels in
mouse models of melanoma and lung cancer [3, 156, 157].
This tumor-induced lymphangiogenesis is controlled by the
stimulation of various lymphatic growth factors secreted by
tumor cells, stroma cells, and inﬂammatory cells in the
tumor microenvironment.
4.3.2. Transdiﬀerentiation from Nonendothelial Cell Types.
Several independent studies have demonstrated signiﬁcant
contribution of bone marrow-derived cells (BMDCs) to the
formation of new blood vessels during tumor angiogenesis
[158, 159]. BMDCs, including endothelial progenitor cells,
are recruited to angiogenic sites to support the formation
of new vessels [158–160]. Endothelial progenitor cells have
beenshowntoplayacriticalroleinregulatingtheangiogenic
switch that eventually aﬀects metastatic progression from
micrometastasis to macrometastasis in mouse models of
pulmonary metastasis [161].
Since there is a biological association between angio-
genesis and lymphangiogenesis, it is important to identify
whether BMDCs also play critical role during pathological
lymphangiogenesis. It has not yet been established whether
expansion of lymphatic vasculature during pathological
conditions is criticallydrivenbyincorporation ofendothelial
progenitor cells. Endothelial progenitor cells are present in
thenewlyformedlymphaticvesselsinacorneallymphangio-
genesis mouse model and also in peritumoral lymphatic ves-
sels of a ﬁbrosarcoma [162]. Remarkably, depletion of bone
marrow cells suppressed lymphangiogenesis in inﬂamed
corneas that were implanted with ﬁbroblast growth factor-
2 (FGF-2) [162]. In another model of mouse inﬂammation
after corneal transplant, Maruyama et al. (2005) showed
that CD11b+ macrophages inﬁltrate the corneal stroma and
transdiﬀerentiate into lymphatic endothelial cells that inte-
grate into existing lymphatic vessels [163]. Study of de novo
lymphangiogenesis in human kidney transplants provided
further evidence for the participation of recipient-derived
lymphatic progenitor cells [164]. Speciﬁcally, myeloid cells
present in murine inﬂamed corneas were found to express
speciﬁc lymphatic marker VEGFR-3, and these speciﬁc cells
also integrate into lymphatic vasculature during inﬂamma-
tion [165].
In a further study using bone marrow transplantation
and genetic lineage-tracing, Zumsteg et al. (2009) demon-
strated that cells derived from the myeloid lineage can con-
tribute to tumor lymphangiogenesis by transdiﬀerentiating
to LECs and incorporating into tumor-associated lymphatics
in a transgenic mouse model of pancreatic β-cell carcinogen-
esis and mouse model of transplanted prostate cancer [166]
(Figure 3(b)).
Plasticity of macrophages has been demonstrated by the
ﬁnding that these cells can transform from na¨ ıve monocytes
into VEGF-C-producing cells. Additionally, TAMs have been
shown to also express the lymphatic marker VEGFR-3 [66].
However,thecontributionofBMDCstotumorlymphangio-
genesis is rather still controversial. In a study using Lewis
lung carcinoma and B16-F1 melanoma cells in syngenic
mice,nointegrationofBMDCsintonewlyformedlymphatic
vessels was detected [156]. Therefore, more studies need to
be performed to validate the transdiﬀerentiation pathway of
TAMs into LECs during tumorigenesis.
Recently, it has been reported that bone marrow-derived
mesenchymal stem cells (MSCs) may also be able to diﬀer-
entiate into endothelial cells (ECs) under certain conditions
[167, 168]. MSCs can form networks in a tube formation
assay in vitro and also highly express endosialin, a tumor
endothelial marker present in the microvascular and stroma
of human tumors [167]. Under hypoxic culture conditions,
human MSCs can diﬀerentiate into endothelial cells and
show a signiﬁcant increase in endothelial speciﬁc markersJournal of Oncology 11
such as CD34, VWF, FLK1, FLT1, TIE2 [168]. Importantly,
MSCsinﬁltratetumorsinhighnumberandhavebeenshown
to enhance breast cancer cell metastasis [169]. These studies
implicate important roles of MSCs during tumorigenesis,
one of which is that MSCs may diﬀerentiate into ECs˜and
thereforecontributetotumorangiogenesisandlymphangio-
genesis. Conversely, ECs treated with bone morphogenetic
protein (BMP4) or TGF-β2c a nb er e v e r t e dt oam u l t i p o t e n t
cell with MSCs phenotype [170]. This indicates that ECs and
MSCs are able to interchange their phenotype. This transd-
iﬀerentiation may be conditioned by the tumor microenvi-
ronment and further contributes to tumor progression.
4.3.3. Transdiﬀerentiation from Blood Endothelial Cells-Endo-
thelial Cell Plasticity. During embryonic lymphangiogenesis,
lymphatic endothelial precursor cells arise from venous
endothelial cells in cardinal vein. Notably, this speciﬁc pop-
ulation of venous endothelial cells expresses several key tran-
scription factors, including SOX18, COUP-TFII, and PROX-
1 that regulate the diﬀerentiation of venous endothelial
cells into LECs [10, 12, 44]. Therefore, under pathological
conditionsintheadult,reactivationofaspeciﬁccombination
of transcription factors may modulate the plasticity of
endothelial cells by turning on the molecular program
required for transition from a BEC phenotype to a LEC fate
(Figure 3(c)).
In support of this concept, the transcription factor
COUP-TFII that is essential for inducing PROX1 expression
in venous endothelial cells and triggering the lymphatic dif-
ferentiationprogram[44]hasbeenalsoshowntoberequired
for adult lymphangiogenesis in an animal model of can-
cer [11]( Table 3). Similarly, although transcription factor
SOX18 is not required for the maintenance of the LEC
phenotype in adult during physiological condition, it is re-
expressed on tumor blood vessels [172] and neolymphatics
(unpublished data) suggesting a potential role in tumor-
induced lymphangiogenesis. Potentially, the re-expression of
SOX18 in BECs may trigger PROX-1 transactivation and
induce the acquisition of a LEC phenotype. Moreover, blood
vessels have been reported to express lymphatic marker
VEGFR-3 in some tumors and chronic wounds [173–175].
TheexpressionofVEGFR-3onBECsnotonlycancontribute
to angiogenenic activation via the VEGF pathway but also
caninducetheLECphenotype,suggestingthatitsexpression
may be indicative of phenotypic transition between blood
and lymphatic vessels.
Although there is no direct evidence so far supporting
the concept of transdiﬀerentiation from BECs, it is plausible
to consider that embryonic lymphatic vascular development
is recapitulated in a tumor setting. Further, experimental
depletion of the venous endothelium or the macrophage
population in a tumor model will yield a deﬁnitive answer
to the question of key cellular diﬀerentiation mechanisms.
Indentifying these diﬀerentiation programs can lead to more
therapeutic options in targeting critical diﬀerentiation path-
ways that trigger lymphangiogenic switch during tumorige-
nesis.
5. Lymphatic Vasculatureasa Potential
Therapeutic Target
5.1. Limitations of Antiangiogenic Therapy. Although it has
been well established in preclinical and clinical studies that
antiangiogenic therapies have antitumoral eﬀects and sur-
vival beneﬁts, it also has emerged that tumor cells can even-
tually elicit multiple mechanisms of resistance that allow
them to adapt to a new milieu. Angiogenic inhibitors (such
as VEGFR2-speciﬁc antibody and sunitinib—an oral, small-
molecule, multitargeted receptor tyrosine kinase inhibitor)
targetingtheVEGFpathwayhavebeenshowntodisplayanti-
tumoreﬀectsinmousemodelsofpancreaticneuroendocrine
carcinoma and glioblastoma but concomitantly induced
tumor progression to greater malignancy with adaptive “eva-
sive resistance” [183]. This mechanism is followed by in-
creased invasion and distant metastasis. Notably, while both
angiogenic inhibitors induced liver metastasis, sunitinib did
not enhance lymph node metastasis [183]. The preferred
explanation for this eﬀect is that sunitinib potently blocks
not only VEGFR-2 and platelet-derived growth factor recep-
tors (PDGFRs) but also speciﬁc lymphatic receptor VEGFR-
3[ 184, 185]. The inhibition of VEGFR-3 in this context
can block tumor lymphangiogenesis and lymph node metas-
tasis. This raises the prospect that a potential therapeutic
strategy could address both blood and lymphatic vessels
to maximize antitumor and antimetastasis eﬀects. Further,
glioblastoma patients involved in antiangiogenic therapies,
including VEGF ligand-trapping antibody and bevacizumab
(a humanized monoclonal antibody that binds to VEGF-
A), showed a proinvasive adaptive response where multifocal
recurrence of tumors developed during the course of the
therapy [186–188].
The critical challenge is to manage metastatic disease
after the primary tumor has been surgically removed or
has been inhibited by antiangiogenic agents. This raises the
question of how anti-lymphangiogenic therapeutics might
help in blocking both lymph node and distant organ me-
tastasis. Hence, the use of antiangiogenic agents could be
considered alongside anti-lymphangiogenic therapeutic ap-
proaches with the aim of improving current therapy.
5.2. Targeting the VEGF Family. A number of independent
studies have now shown that inhibiting tumor-induced neo-
lymphangiogenesis can dramatically reduce the metastatic
spread of cancer in mouse models [83, 189, 190]( s e e[ 191]
forreview).Recently,severaltherapeuticstrategiesthattarget
outgrowth of lymphatics via the VEGFR-3/VEGF-C/VEGF-
D axis have been developed, based on preclinical animal
models (Table 4) or on clinical trials using VEGFR tyrosine
kinase inhibitors (Table 5). It is important to note that
VEGF-C/VEGFR-3 signalling is not required for the main-
tenance of lymphatic vasculature in the adult, as prolonged
inhibition of the VEGFR-3 pathway using soluble VEGFR-3
decoy receptor does not aﬀect preexisting lymphatic vessels
in the adult [192].
In preclinical studies, the therapeutic eﬀects of targeting
VEGFpathwayshavebeenevaluatedusingantibodiestoneu-
tralize lymphatic growth factors/receptor, or a soluble form12 Journal of Oncology
Table 3: Tumor lymphangiogenic transcription factors.
Transcription
factors Target genes Association with cancer References
PROX-1
Genes involved in proteolysis,
lymphatic diﬀerentiation, cell
adhesion, and migration
(i) Prox1 is strongly expressed by human Kaposi’s sarcoma
(a neoplasm of KSHV-infected vascular endothelium). (∗)
(ii) Highly expressed Prox1 induces lymphatic
reprogramming, more aggressive tumor growing, and
local invasion.
[176, 177]
SOX18 Prox-1, VCAM-1, Claudin-5
(i) SOX18 plays a critical role in initial steps of tumor
angiogenesis and subsequent induction of tumor growth.
(ii) SOX18 has also been found to express on tumor
neolymphatics, suggest its potential role in regulation of
tumor lymphangiogenesis.
[172, 178,
179]
(unpub-
lished
data)
COUP-TFII
( i )N r p 2 ,c o r e c e p t o rf o rV E G F - C
(ii) Suppress VEGFR-1
expression in ECs
(i) Essential factor for tumor-induced
neo-lymphangiogenesis in spontaneous mouse breast
cancer model
(ii) Control pancreatic islet tumor angiogenesis by
regulating VEGF/VEGFR-2 signalling
[11, 180]
FOXC2 Integrin β3 subunit, Dll4, Hey2,
CXCR4
(i) FOXC2 might regulate tumor angiogenesis by target
genes including integrin β3, CXCR4, and Delta-like 4
(Dll4).
(ii) High FOXC2 expression (mRNA level) group showed
a higher incidence of advanced tumor stage, lymph node
metastasis, and lymphatic invasion in esophageal cancer
patients.
[181, 182]
∗KSHV:Kaposi’ssarcoma-associatedherpesvirus(theinvolvementoflymphatictranscriptionfactors—NFATc1andTbx1—incancermetastasishasnotbeen
reported recently).
Prognostic indicators
for tumor progression
∗Antiangiogenesis
∗Antilymphangiogenesis
∗Chemotherapy
∗Antiangiogenesis
∗Antilymphangiogenesis
∗Chemotherapy
PDT Surgery
Monitor cancer
recurrence
(A) Cancer prognosis (B) Pretreatment (C) Treatment (D) Posttreatment
- Sentinel LN status
- Lymphangiogenic GFs
- Tumor-associated LVD
- Intralymphatic cancer cells
- LN lymphangiogenesis
- Reduce tumor growth rate
and tumor size
- Restrict metastasis
Target
intralymphatic
cancer cells
Remove primary
tumor, (+)LN
Restrict tumor regrowth and
reduce high risk of recurrence
- Sentinel LN status
- Lymphangiogenic GF
level
- Angiogenic GF level
Figure 4: Schematic for potential clinical strategies in treatment of metastatic disease. (A) Tumor progression can be evaluated based on
several prognostic indicators including tumor lymphangiogenesis and sentinal LNs status. These steps will guide the therapeutic decision to
adopt anti-lymphangiogenic strategies if the tumor appears to be lymphangiogenesis-dependent and/or to have lymph node metastasis. (B)
Antiangiogenesis, anti-lymphangiogenesis, and chemotherapy can be applied to reduce tumor growth and restrict metastasis before surgery.
For advanced disease or nonresectable tumors, there will be no surgery [171]. (C) Photodynamic therapy (PDT) also can be performed
before removal of the primary tumor, to eradicate in-transit tumor cells and prevent tumor relapse. Anti-lymphangiogenic, antiangiogenic,
and chemotherapy can also be applied later, to prevent tumor regrowth and metastasis. (D) Cancer recurrence can be monitored by checking
sentinel LN status, lymphangiogenic and angiogenic growth factor levels. PDT, photodynamic therapy; LN, lymph node; LVD, lymphatic
vessel density; GF, growth factor (adapted from [171]).
of VEGFR-3 to trap VEGF-C/D. Neutralization of VEGF-
D with a speciﬁc antibody or genetic ablation of VEGF-D
appearstosuppresstumormetastasisinmice[100,204,205].
Further, anti-VEGF-R3-blocking antibody or VEGF-C/-D
trap strategy (a soluble VEGF-R3 immunoglobulin G Fc-
domain fusion protein) has been shown to reduce the rate
of lymph node metastasis in mouse models by 60–70%
[3, 129, 157, 192, 197, 206, 207]( s e e[ 51] for review).
Further, VEGF-C has been known to also bind to Nrp-2
coreceptor and play a role in regulation of small lymphatic
vessel and capillary remodelling [29, 208]. An antibody
against the Nrp-2 coreceptor that blocks VEGF-C binding
hasbeenshowntoreducetumorlymphangiogenesisandme-
tastasis to regional lymph nodes and distant organs [189].
Targeting Nrp-2 therefore has been considered as a potential
w a yt ob l o c kt u m o rs p r e a dvia inhibition of neo-lymphangi-
ogenesis.
Another indirect approach is to target the pathway
controlling VEGF-C/-D proteolysis. Proteolysis improves the
aﬃnity of VEGF-C and -D for both VEGFR-2 and VEGFR-
3, which can further increase the induction of these growth
factors during tumor angiogenesis and lymphangiogenesisJournal of Oncology 13
Table 4: Preclinical studies of anti-lymphangiogenic eﬀect on tumor metastasis.
Drugs Experiment/cancer model Eﬀect References
siRNA VEGF-C Mouse mammary tumor model
(C166-siVEGFC)
Reduction in tumor lymphangiogenesis, lymph
node metastasis, and spontaneous lung
metastasis
[193]
Human
monoclonal
antibody VC
(anti-VEGF-C)
In vitro binding aﬃnity of
antibody was tested
(i) Bind with high speciﬁcity and aﬃnity to full
processed mature form of human VEGF-C
(ii) Inhibit the binding of VEGF-C to
VEGFR-2 and VEGFR-3
[194]
VEGFR31-Ig
Mouse model of a highly
metastatic human hepatocellular
carcinoma (HCCLM3)
(i) Simultaneously bind VEGF-A, VEGF-C.
(ii) Block both tumor angiogenesis and
lymphangiogenesis, eﬀectively inhibit primary
tumor growth, metastasis to lung and lymph
node
[195]
VD1
monoclonal Ab
(anti-VEGF-D)
Immunodeﬁcient mice, 293EBNA
express VEGF-D (mAbs raised to
VDH of hVEGF-D (antagonists))
Reduce the LN metastasis from 61% to 0% [98]
Monoclonal Ab
to VEGFR-3
Regeneration of adult lymphatic
vessels
Block the regeneration of lymphatic vessels in
adult [196]
VEGFR-3
monoclonal
antibody
Mouse model of
MDA-MB-435/GFP human breast
cancer transfected with human
VEGF-C cDNA
Suppress tumor lymphangiogenesis and
restrict metastatic spread to lymph nodes and
distant organs
[197]
Soluble
VEGFR-3
(VEGFR-3-Ig)
Highly metastasis human lung
cancer cells (LNM35) stably
expressing VEGFR-3-Ig or
recombinant adenovirus
expressing VEGFR-3-Ig were
injected to LNM35 tumor-bearing
mice
(i) Inhibition of intra- and peritumoral
lymphangiogenesis
(ii) Metastasis to LN was inhibited
(iii) Metastasis to lung occurred in all mice
group
[198]
Soluble
VEGFR-3
(VEGFR-3-Rg)
Immunocompetent rat model
induced with highly metastatic
MT-450 cancer cells expressing
VEGFR-3 soluble
(i) Reduction in the number of peritumor
lymphatic vessels
(ii) Suppression of metastasis formation both
in regional LNs and lungs
[199]
Soluble
VEGFR-3 decoy
receptor
(sVEGFR3-Fc)
Mouse model of human
melanoma, human prostate
injected with recombinant
adeno-associated viral vector
sVEGFR3-Fc (rAAV-sVEGFR3-Fc)
Treatment before tumor
implantation
(i) Melanoma: inhibit LN metastasis, but have
less eﬀect on lung metastasis
(ii) Prostate: inhibit LN and lung metastasis
(iii) Inhibition of tumor-associated
lymphangiogenesis
[192]
Soluble
VEGFR-3
Mouse model of prostate cancer
(PC-3): subcutaneously or surgical
orthotopic implantation
Reduction in intratumoral lymphatics, but
metastasis to LN was not signiﬁcantly aﬀected [200]
Ki23057
M o u s em o d e lo fg a s t r i cc a n c e r
induced by orthotopic inoculation
of OCUM-2MLN cells
(i) Ki23057 is a tyrosine kinase inhibitor, block
autophosphorylation of VEGFR-3
(ii) Reduced signiﬁcantly lymphatic invasion
and lymphangiogenesis
(iii) Reduced size of orthotopic tumors and
number of metastatic LN
[201]
Anti-
neutropilin-2
Mouse model of breast
adenocarcinoma (66C14) and
rodent glioblastoma (C6)
Reduction in tumor lymphangiogenesis,
metastasis to sentinel lymph nodes and distant
organs
[189]
Celecoxib
(COX-2
inhibitor)
Mouse model of highly metastasis
human lung adeocarcinoma
Suppression of the lymphangiogenesis and
lymph node metastasis through
downregulation of VEGF-C expression.
[202]
Antagonists of
integrin α4β1
Mouse model of Lewis lung
carcinoma and B16 melanoma
cancer
Signiﬁcant suppression of lymphangiogenesis
and metastasis [203]14 Journal of Oncology
Table 5: Clinical trials of tyrosine kinase inhibitors on the VEGF pathway.
Drugs Clinical trials Target References
PTK787/ZK 222584
(chloroanilino-pyridylmethyl
phthalazine succinate)
Phase III for colorectal cancer Phase I, II for
advanced hepatocellular carcinoma patients (in
combination with intravenous doxorubicin)
Target VEGFR-3, -2, -1, PDGFR-beta
(need new strategies for trials to
speciﬁcally monitor eﬀects on metastasis)
[210, 211]
CEP-7055 (N, N-dimethyl glycine
ester)
Phase I as an oral-administered therapy for
various malignancies Target VEGFR-3, -2, -1 [212]
BAY 43-9006 (Bi-aryl urea)
Phase III for renal cell carcinoma
Phase II for multiple tumor types (e.g., prostate,
ovarian, pancreatic, breast, and lung cancers...)
Target VEGFR-3, -2 tyrosine kinase,
PDGFR-beta, FGFR-1 [213]
JNJ-26483327 Phase I for patients with advanced solid tumors
Multitargeted tyrosine kinase inhibitor,
inhibiting kinase of (EGFR)-1, -2, -4;
VEGFR-3, Src family (Lyn, Fyn, Yes)
[214]
SU-014813 Phase I for patients with advance solid tumors Oral multitargeted tyrosine kinase
inhibitor [215]
(modiﬁed from the table in paper “Focus on lymphangiogenesis in tumor metastasis”- Cancer cell, Achen et al., 2005 [206]).
[94, 108]. Recently, a novel enediynyl peptide inhibitor has
been developed to block the furin-mediated processing of
pro-VEGF-C to mature VEGF-C [209]; further studies using
animal models need to be performed to clarify the in vivo
eﬀect and mechanism of this inhibition.
To date, several VEGF-receptor tyrosine-kinase inhibi-
tors have entered phase I, II, or III clinical trials for cancer
treatment, including BAY 43-9006, CEP-7055, PTK787/ZK
222584, JNJ-26483327, and SU-014813 (Table 5). These
VEGF-receptor tyrosine-kinase inhibitors are well tolerated,
display low toxicity and positive results such as an increase in
response rate, progression-free survival, and overall survival,
and have been observed in advanced colorectal, renal cell,
breast, and non-small-cell lung cancer. This response is ob-
served when treatment of VEGF-receptor tyrosine-kinase
inhibitors is used alone or in combination with chemother-
apy [216]. Although these multiple VEGF-receptor tyrosine-
kinaseinhibitorsalsoaﬀecttumorlymphangiogenesisviathe
VEGFR-3 pathway, most clinical investigations have focused
on antiangiogenic and antitumor growth eﬀects, and only
a handful of reports describe antilymphangiogenic eﬀect or
anti-metastatic outcomes. More clinical evaluations on these
tumor lymphatic aspects are required to develop a more
eﬃcienttherapeuticapproachagainsttumorgrowthandme-
tastasis.
5.3. New Targets for Anti-Lymphangiogenesis . Over the past
two decades,many key factorshave been identiﬁed as impor-
tant regulators for tumor lymphangiogenesis (Tables 2 and
3), but the major focus in anti-lymphangiogenic therapy has
been targeting through VEGF-C and -D, and their mem-
brane receptor VEGF-R3 and coreceptor (Nrp-2) [157,
206, 217]. Blocking only a single pathway related to the
VEGF/VEGFR axis may not always be eﬀective to prevent
cancer metastasis. For instance, the lack of eﬀect of PTK/ZK
(a broad spectrum inhibitor of VEGF signalling) on tumor
lymphangiogenesis and lymphatic metastasis in a mouse
modelofpancreaticβ-cellcarcinomasoverexpressingVEGF-
C or VEGF-D reveals the involvement of other pathways
[218]. Adenoviral delivery of soluble VEGFR-3 also did
not inhibit tumor lymphangiogenesis in these mice. This
result suggests that the level of VEGF-C/D expression might
be critical for drug eﬀects and that there might be other
important pathways involved in tumor lymphangiogenesis.
Various endogenous inhibitors of angiogenesis have
been identiﬁed so far including matrix-derived group (e.g.,
collagen fragments, endostatin, tumstatin, ...), and non-
matrix-derived group (e.g., interferons, angiostatin, ...)
[219]; however, little is known about endogenous inhibitors
oflymphangiogenesis.Usingamousecorneamodelinwhich
lymphangiogenesis is induced by factors including VEGF-
A, FGF-2, and PDGF-BB, Vasohibin1 has been shown to
have broad-spectrum anti-lymphangiogenic activity [220].
Vasohibin1 also appears to inhibit tumor lymphangiogenesis
and regional lymph node metastasis in a mouse model
of human lung cancer [220] .T h e r ei san e e dt oi d e n t i f y
novel endogenous lymphangiogenic inhibitors to broaden
the therapeutic options in anticancer metastatic treatment.
Conspicuously, the current knowledge of the transcrip-
tional control of pathological lymphangiogenesis has been
disregarded, limiting the range of potential novel therapeutic
targets. Recent studies have revealed the role of transcrip-
tion factors in controlling neolymphatic formation during
tumorigenesis. For instance, COUP-TFII has been shown to
play a critical role in tumor lymphangiogenesis in a mouse
model [11]. In addition, SOX18, a transcription factor regu-
latingearlyvasculogenesis[221,222]andlymphangiogenesis
in the embryo [10], has been also identiﬁed to play a critical
roleintheinitialstepsoftumorangiogenesisandsubsequent
induction of the tumor growth. Sox18-mutant mice show
greatly reduced tumor diameter compared to wild type
[172]. The reexpression of SOX18 on tumor neo-lymphatics
(unpublished data) suggests there might be an additional
role of SOX18 in controlling tumor lymphangiogenesis.
Considering that FOXC2 also plays a critical role during
embryonic blood and lymphatic vessel development [17,
223], there is also evidence for the involvement of this
transcription factor during tumor growth and angiogenesis.
Forinstance,inaggressivebasal-likebreastcancers,FOXC2is
also highly expressed and contributes to cancer invasion and
metastasis [224]. The tumoral endothelium in human and
mouse express FOXC2, and Foxc2 +/− heterozygous mutantJournal of Oncology 15
mice display reduced tumor growth due to a decrease in
neoangiogenic activity [225]. The growing body of evidence
supporting a critical of role of transcription factors as mod-
ulators of tumor-induced lymphangiogenesis provides new
potential avenues in the design of novel therapeutic strate-
gies. Engineering new ways to target transcription factors
pharmacologically therefore represents an essential step to-
wards further complementing therapeutic inhibition of the
VEGF-VEGF-R axis.
Recent studies have broadened our knowledge about the
molecular pathways that regulate tumor lymphatic forma-
tion and lymphatic spread. These include not only the group
of lymphatic growth factors (Table 2) but also several tran-
scriptional regulators (Table 3). In considering therapeutic
application, targeting transcriptional factors may encounter
the diﬃculty in delivery, as drugs need to be delivered to
nucleus to be able to block the transcriptional factor tar-
gets. Nevertheless, further preclinical studies targeting both
growth factors and transcription factors with an eﬃcient
delivery system may potentially inhibit tumor lymphangio-
genesisandthereforemetastasis.Additionally,furtherstudies
on the role of other groups of transcription factors that
control tumor angiogenesis and tumor lymphangiogenesis
will generate new therapeutic options for inhibiting the
metastasis of solid tumors.
6. Summary and Conclusions
In preclinical studies using animal models, a variety of
approaches have been investigated mainly targeting pro-
lymphangiogenic signalling related to the VEGF axis, includ-
ing neutralization using monoclonal antibodies, soluble
receptors, chemical inhibitors, and shRNA. The next chal-
lenge is to establish translational studies to address metas-
tasis via a more integrative approach that inhibit multiple
pathways(relatedtobothlymphaticgrowthfactorsandtran-
scription factors) modulating tumor lymphangiogenesis. An
anti-lymphangiogenic approach could be used together with
antiangiogenic therapy and conventional chemotherapy,
leading to a more eﬃcient way to prevent cancer recurrence
[171]. Recently, in a mouse model of gastric cancer, the
combination of treatment with antiangiogenic agent (beva-
cizumab) and genetic blockade of IGF-1 (IGF-1R dominant
negative) eﬃciently reduced tumor growth and importantly
resulted in the complete regression of 43% of tumors by
inhibiting both angiogenesis and lymphangiogenesis [114].
In humans, the beneﬁt of treatments that combine sunitinib
(an anti-angiogenic agent) with docetaxel (an anti-mitotic
chemotherapeutic) has been evaluated in phase 1/2 clinical
trialsofprostatecancerpatients.Thiscombinationwasmod-
erately well tolerated and showed a promising increase of
progression-free survival [226].
Based on the most recent preclinical research, photo-
dynamic ablation of in-transit metastatic cancer cells could
also be applied to eﬃciently prevent the recurrence of cancer
metastasis (Figure 4). This method relies on liposomes,
which ensure lymphatic speciﬁc delivery of verteporﬁn, a
drug that can be activated by a 689nm laser light. The cyto-
toxic activity of light-activated verteporﬁn is thus restricted
to lymphatic vessels and cancer cells within the vessel. This
preclinical study on a mouse model has shown that the
recurrent metastasis was reduced to 37.5% compared to
untreated animals after laser treatment [227].
To advance the prospect of anti-lymphangiogenic ther-
apy, the next step would be to initiate trials on cancer types
in which lymphangiogenesis has been clearly identiﬁed as a
risk factor. Moreover, there are still several issues that need
to be clariﬁed which relate to the eﬃciency of anti-lymphan-
giogenic therapy in blocking metastasis. Firstly, inhibition
of lymphangiogenesis does not seem to aﬀect preexisting
vessels [196], which are still potential routes for cancer cell
dissemination. Secondly, there are some possible side eﬀects
of targeting tumor-associated lymphatic vessels [228]. Inhi-
bition of lymphangiogenesis might interfere with physiolog-
ical process such as wound healing and tissue regeneration
[173]. Finally, lymphedema is a complication in 20%–30%
of breast cancer patients after surgery to remove the tumor-
metastasized lymph node [229, 230]. Therefore, preclinical
studies using animal models have been performed in an
attempt to restore lymphatic vessel function in secondary
lymphedema, including VEGF-C, VEGF-D gene transfer
usingadenovirusornakedplasmidsandrecombinantVEGF-
Cp r o t e i n[ 3, 231].
In conclusion, the study of embryonic lymphatic vessel
development has revealed key factors that play a central role
in controlling tumor-induced lymphangiogenesis. However
only the VEGF/VEGF-R axis has been thoroughly investi-
gated and exploited with a view to restricting tumor growth
and metastasis, and so far the outcomes in terms of patient
survival have been limited. Therefore, it is important to con-
tinue eﬀorts to indentify factors and molecular mechanisms
in order to fully comprehend how tumor neo-lymphan-
giogenesis is regulated and participates in tumor metastasis.
These discoveries will lead to identiﬁcation of potential new
molecular targets and design of novel therapeutic avenues
of metastatic disease. In addition, further preclinical studies
focusing on delivery systems, side eﬀects, drug resistance,
and combination of anti-angiogenic and anti-lymphangiog-
enic therapies may eventually improve the eﬃcacy of current
treatments.
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